The Predictive Value of HER2 in Breast Cancer

@article{Piccart2001ThePV,
  title={The Predictive Value of HER2 in Breast Cancer},
  author={M. Piccart and C. Lohrisch and A. Di Leo and D. Larsimont},
  journal={Oncology},
  year={2001},
  volume={61},
  pages={73 - 82}
}
  • M. Piccart, C. Lohrisch, +1 author D. Larsimont
  • Published 2001
  • Medicine
  • Oncology
  • Measurement of molecular markers predictive of response to therapy should enable more selective and effective utilization of anticancer agents. The predictive value of HER2 remains a complex and inconclusive subject. In metastatic breast cancer, HER2-positive, ER-positive patients can show responses to endocrine treatment, but experience shorter time to progression and survival than HER2-negative patients. In the adjuvant setting, weak, retrospective evidence suggests that tamoxifen is… CONTINUE READING
    144 Citations
    HER2 Testing in Breast Cancer: Opportunities and Challenges
    • 6
    • PDF
    Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe
    • 25
    Testing for HER2 Status
    • 62
    • Highly Influenced
    HER2 as a Predictive Factor for Successful Neoadjuvant Anthracycline Chemotherapy of Locally Advanced and Early Breast Cancer
    • J. Wang, B. Xu, +6 authors Y. Luo
    • Medicine
    • The International journal of biological markers
    • 2014
    • 3
    Targeted therapy of breast cancer.
    • 17
    Endocrine resistance in breast cancer – An overview and update
    • 174
    • PDF

    References

    SHOWING 1-10 OF 59 REFERENCES
    Assessment of HER2 status in breast cancer: why, when and how?
    • 120
    Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe
    • 25
    Testing for HER2 Status
    • 62
    The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.
    • A. Hamilton, M. Piccart
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2000
    • 184
    HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    • R. Elledge, S. Green, +8 authors C. Osborne
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 1998
    • 295
    • PDF
    p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    • 176
    Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
    • H. Yamauchi, A. O'Neill, +4 authors D. Hayes
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1997
    • 261
    Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
    • M. Cobleigh, C. Vogel, +8 authors D. Slamon
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1999
    • 2,722
    erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
    • 615
    • PDF
    Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
    • 216
    • PDF